Merrimack Initiates Phase 2 Clinical Study of MM-111 in Advanced Gastroesophageal Cancers
July 22, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 22, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the enrollment of its first patient in a Phase 2 clinical trial of its bispecific...
Merrimack Closes Concurrent Sale of 5,750,000 Shares of Common Stock and $125,000,000 Aggregate Principal Amount of Convertible Senior Notes
July 17, 2013 16:15 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 17, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the closing of its sale of 5,750,000 shares of its common stock at a price to the...
Merrimack Prices Concurrent Public Offerings of 5,000,000 Shares of Common Stock and $125,000,000 Aggregate Principal Amount of Convertible Senior Notes
July 11, 2013 23:52 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 11, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it has priced concurrent public offerings of 5,000,000 shares of its common stock...
Merrimack Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes
July 10, 2013 16:01 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., July 10, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced its intention to offer, subject to market and other conditions, $50 million of its...
Merrimack to Present at the Goldman Sachs 34th Annual Global Healthcare Conference
June 06, 2013 12:07 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., June 6, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that William Sullivan, CFO, is scheduled to present at the Goldman Sachs 34th Annual...
Merrimack Pharmaceuticals' Phase 1 Research Supports MM-121 Potential for Investigation as Combination With Chemotherapy in Patients With Advanced Solid Tumors
June 04, 2013 09:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., June 4, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be...
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast Cancer
May 23, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., May 23, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in a Phase 2 randomized, double blind clinical...
Merrimack Reports First Quarter 2013 Financial Results
May 13, 2013 10:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., May 13, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
Merrimack to Present at Multiple Investor Conferences This Spring
May 02, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that their management team is scheduled to present at multiple investor conferences this...
Merrimack Pharmaceuticals Announces Timing of First Quarter 2013 Investor Conference Call
April 30, 2013 10:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its First Quarter 2013 Investor Conference Call and...